美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

罗氏控股

41.33

+0.25000.61%

盘后：41.330.00000.00%16:00 EDT

成交量：267.32万

成交额：1.11亿

市值：2,675.72亿

市盈率：26.65

高：41.67

开：41.65

低：41.20

收：41.08

数据加载中...

总览公司新闻公告

罗氏(RHHBY)计划未来五年在美国投资500亿美元

罗氏制药(RHHBY.US)罗可适®在华获批用于治疗复发型和原发进展型多发性硬化症

罗氏(RHHBY.US)口服PI3Kα抑制剂“伊那利塞”国内获批上市

罗氏(RHHBY.US)突破性疗法递交监管申请

罗氏(RHHBY.US)创新疗法获FDA批准用于治疗成人急性缺血性中风

“减脂不减肌”：药企竞逐下一代减肥药新突破

老虎资讯综合

FDA批准罗氏(RHHBY.US)旗下公司的Evrysdi片剂新药申请用于治疗脊髓性肌萎缩症患者

罗氏(RHHBY.US)CD20单抗“奥妥珠单抗”申报狼疮性肾炎新适应症

FDA已批准罗氏(RHHBY.US)旗下基因泰克的Susvimo用于治疗糖尿病性黄斑水肿

罗氏预计2025年销售额中单位数增长，核心每股收益高单位数增长

罗氏第四季度调整后每股收益从去年同期的18.57瑞士法郎上升至18.80瑞士法郎，销售额从58.72亿美元上升至60.49亿美元

估值洼地之下，2025年这些生物科技股股价有望突破

老虎资讯综合

罗氏(RHHBY.US)CEO回应增长问题：公司没有裁员计划业务很健康

罗氏(RHHBY)莫妥珠单抗注射液在华批准上市

罗氏(RHHBY.US)双抗癌症疗法“莫妥珠单抗”在中国获批上市

罗氏(RHHBY.US)达成近9亿美元合作开发自身免疫性疾病疗法

罗氏(RHHBY)拟收购生物制药企业Poseida Therapeutics

罗氏将以15亿美元的价格收购美国生物制药公司Poseida

老虎资讯综合

罗氏(RHHBY.US)达成抗癌小分子研发合作或投资超18亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/RHHBY/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"罗氏控股","latestPrice":41.33,"timestamp":1746475200000,"preClose":41.08,"halted":0,"volume":2673237,"hourTrading":{"tag":"盘后","latestPrice":41.33,"preClose":41.33,"latestTime":"16:00 EDT","volume":4675,"amount":193094.55,"timestamp":1746475225128},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"未开盘","change":0.25,"latestTime":"05-05 16:00:00 EDT 延时","open":41.65,"high":41.67,"low":41.2,"amount":110568364.83299999,"amplitude":0.011441,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1746518400000},"marketStatusCode":0,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":41.08,"volumeRatio":1.090165},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":1.090165,"shares":6474029800,"dividePrice":1.472137,"high":41.67,"amplitude":0.011441,"preClose":41.08,"low":41.2,"week52Low":29.715,"pbRate":"6.94","psRate":"3.53","week52High":44.31,"institutionHeld":0,"latestPrice":41.33,"eps":1.550894,"divideRate":0.035619,"volume":2673237,"delay":15,"ttmEps":1.550894,"open":41.65,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":40.51,"twentyDayClose":37.65,"sixtyDayClose":39.61},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529634009","title":"罗氏(RHHBY)计划未来五年在美国投资500亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529634009","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529634009?lang=zh_cn&edition=fundamental","pubTime":"2025-04-22 16:41","pubTimestamp":1745311271,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据外媒报道，罗氏控股(RHHBY)未来五年将在美国投资500亿美元用于制药和诊断业务，相关计划包括扩大和升级肯塔基州、印第安纳州、新泽西州、俄勒冈州和加利福尼亚州的制造和分销能力。罗氏还计划建立一家生产工厂，以支持下一代减肥药的扩产，但没有透露工厂的位置。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2523942971","title":"罗氏制药(RHHBY.US)罗可适®在华获批用于治疗复发型和原发进展型多发性硬化症","url":"https://stock-news.laohu8.com/highlight/detail?id=2523942971","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523942971?lang=zh_cn&edition=fundamental","pubTime":"2025-03-31 21:19","pubTimestamp":1743427176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏制药今日宣布，其旗下创新药罗可适正式获得中国国家药品监督管理局批准，每六个月静脉输注一次给药，用于治疗成人复发型多发性硬化症和成人原发进展型多发性硬化症，中国多发性硬化症患者将有望获得全球先进的全新治疗选择。复发型多发性硬化症病程反复发作，最终可能导致永久性残疾;原发进展型多发性硬化症患者自发病开始，病情会持续进展恶化，患者运动、感觉和认知功能持续下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1271992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","RHHBY","BK4007","BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2519819196","title":"罗氏(RHHBY.US)口服PI3Kα抑制剂“伊那利塞”国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2519819196","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519819196?lang=zh_cn&edition=fundamental","pubTime":"2025-03-14 10:49","pubTimestamp":1741920588,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月14日，罗氏(RHHBY.US)宣布， PI3Kα 抑制剂“伊那利塞”获批上市，与哌柏西利和氟维司群(内分泌疗法)联合用药治疗内分泌治疗耐药(包括在辅助内分泌治疗期间或之后出现复发)、 PIK3CA 突变、激素受体(HR)阳性、人表皮生长因子受体 2(HER2)阴性、局部晚期或转移性乳腺癌成人患者(受理号：JXHS2400037/8)。伊那利塞是一种创新口服靶向治疗药物，对 PI3Kα 的抑制有高效力和特异性，同时有独特的作用机制可降解 PI3Kα 突变体，能为 HR 阳性、PIK3CA 突变的乳腺癌患者提供良好的耐受性、持久的疾病控制并有可能改善预后。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1261810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)口服PI3Kα抑制剂“伊那利塞”国内获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2517543461","title":"罗氏(RHHBY.US)突破性疗法递交监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2517543461","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517543461?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 20:48","pubTimestamp":1741265300,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏今天宣布，美国FDA已接受该公司为抗CD20抗体obinutuzumab递交的补充生物制品许可申请，用于治疗狼疮性肾炎。新闻稿指出，obinutuzumab是首个在狼疮性肾炎随机3期临床试验中显示出完全肾脏缓解益处的抗CD20单克隆抗体。在狼疮性肾炎中，致病B细胞驱动持续性炎症，从而损伤肾脏。通过使用obinutuzumab耗竭致病B细胞，可针对狼疮性肾炎的根本原因，以帮助更好地控制该疾病，保护肾脏免受进一步损伤，并可能预防或延缓疾病进展至终末期肾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)突破性疗法递交监管申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2516675706","title":"罗氏(RHHBY.US)创新疗法获FDA批准 用于治疗成人急性缺血性中风","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675706","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675706?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 21:04","pubTimestamp":1741093486,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏旗下基因泰克宣布，美国FDA已批准血栓溶解剂TNKase上市，用于治疗成人急性缺血性中风。新闻稿指出，TNKase是FDA近30年来批准的首款中风药物。TNKase通过一次五秒的静脉推注给药，与同为罗氏开发的标准治疗Activase相比，这种给药方式更快速和便捷。TNKase以一次五秒的静脉推注给药，启动一种能够分解血栓成分纤维蛋白的生化反应。研究结果显示，在急性缺血性中风患者中，TNKase在安全性和疗效方面与Activase相当。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"罗氏(RHHBY.US)创新疗法获FDA批准 用于治疗成人急性缺血性中风","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"1166835000","title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1166835000","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166835000?lang=zh_cn&edition=fundamental","pubTime":"2025-02-20 17:58","pubTimestamp":1740045485,"startTime":"0","endTime":"0","summary":"罗氏计划今年启动中期试验，将其与自研GLP-1减肥候选药CT-388联用。BiohavenBiohaven在一项早期肥胖试验中评估其靶向肌肉生长抑制素的药物taldefgrobep alfa。该药虽未改善脊髓性肌萎缩症患者的运动功能，但减少了总体脂肪量，并在去脂体重和骨密度方面优于安慰剂。公司将在男性肥胖患者的早期研究中评估安全性，数据预计2025年一季度公布。","market":"us","thumbnail":"https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","KROS","RHHBY","ARWR","AZN","ELAB","VERU","REGN","LLY"],"gpt_icon":1},{"id":"2511581530","title":"FDA批准罗氏(RHHBY.US)旗下公司的Evrysdi片剂新药申请 用于治疗脊髓性肌萎缩症患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2511581530","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511581530?lang=zh_cn&edition=fundamental","pubTime":"2025-02-13 08:06","pubTimestamp":1739405187,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏旗下基因泰克公司今日宣布，美国FDA已批准Evrysdi片剂的新药申请，用于治疗脊髓性肌萎缩症患者。新闻稿指出，Evrysdi是首款改变SMA疾病进程的非侵入性治疗药物。Evrysdi片剂既可整片吞服，也可溶解于水中服用。这意味着服用该片剂的患者可获得与Evrysdi口服液相同的既定疗效和安全性。对于使用其他剂量Evrysdi以及可能更倾向于口服液的患者，Evrysdi口服液仍将保持供应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1249150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA批准罗氏(RHHBY.US)旗下公司的Evrysdi片剂新药申请 用于治疗脊髓性肌萎缩症患者","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2510858088","title":"罗氏(RHHBY.US)CD20单抗“奥妥珠单抗”申报狼疮性肾炎新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2510858088","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510858088?lang=zh_cn&edition=fundamental","pubTime":"2025-02-10 14:12","pubTimestamp":1739167931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，罗氏公布奥妥珠单抗治疗活动性狼疮肾炎患者的III期REGENCY研究的详细分析，并发表于《新英格兰医学杂志》。罗氏表示，奥妥珠单抗是全球首款在狼疮性肾炎随机III期临床试验中证明完全肾脏缓解获益的CD20单抗。根据2024年财报，罗氏已于2024年12月向FDA递交狼疮性肾炎新适应症的上市申请。这意味着，奥妥珠单抗将成为首个获得FDA批准用于治疗狼疮性肾炎的CD20靶向疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2509286362","title":"FDA已批准罗氏(RHHBY.US)旗下基因泰克的Susvimo用于治疗糖尿病性黄斑水肿","url":"https://stock-news.laohu8.com/highlight/detail?id=2509286362","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509286362?lang=zh_cn&edition=fundamental","pubTime":"2025-02-05 21:11","pubTimestamp":1738761117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，当地时间 2 月 4 日，罗氏旗下基因泰克宣布，FDA 已批准 100 mg/mL Susvimo用于治疗糖尿病性黄斑水肿。新闻稿指出，Susvimo是首个也是唯一一个可替代常规眼部注射治疗 DME 的持续给药治疗药物，每年仅需治疗两次，即可帮助 DME 患者维持视力。目前 Susvimo 已在美国获批两项适应症：湿性年龄相关性黄斑变性和糖尿病性黄斑水肿  。此次获批是基于一项 III 期 Pagoda 一年期临床研究的积极结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA已批准罗氏(RHHBY.US)旗下基因泰克的Susvimo用于治疗糖尿病性黄斑水肿","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"1156604397","title":"罗氏预计2025年销售额中单位数增长，核心每股收益高单位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1156604397","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156604397?lang=zh_cn&edition=fundamental","pubTime":"2025-01-30 16:08","pubTimestamp":1738224508,"startTime":"0","endTime":"0","summary":"该公司预计，到2025年销售额将实现中单位数增长，核心每股收益将实现高单位数增长，并且瑞士法郎股息将进一步增加。以上内容来自Benzinga Earnings专栏，原文如下：For 2025, the company expects mid-single-digit sales growth and high-single-digit core EPS growth, with a further increase in dividends in Swiss francs.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBF","RHHBY","RHHVF"],"gpt_icon":0},{"id":"1102683662","title":"罗氏第四季度调整后每股收益从去年同期的18.57瑞士法郎上升至18.80瑞士法郎，销售额从58.72亿美元上升至60.49亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102683662","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102683662?lang=zh_cn&edition=fundamental","pubTime":"2025-01-30 16:04","pubTimestamp":1738224266,"startTime":"0","endTime":"0","summary":"罗氏第四季度调整后每股收益从去年同期的18.57瑞士法郎上升至18.80瑞士法郎，销售额从58.72亿美元上升至60.49亿美元以上内容来自Benzinga Earnings专栏，原文如下：Roche's Q4 Adj. EPS CHF18.80 Up From CHF18.57 YoY, Sales CHF60.49B Up From CHF58.72B YoY","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏第四季度调整后每股收益从去年同期的18.57瑞士法郎上升至18.80瑞士法郎，销售额从58.72亿美元上升至60.49亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBF","RHHVF","RHHBY"],"gpt_icon":0},{"id":"1131960883","title":"估值洼地之下，2025年这些生物科技股股价有望突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1131960883","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131960883?lang=zh_cn&edition=fundamental","pubTime":"2024-12-30 11:23","pubTimestamp":1735529035,"startTime":"0","endTime":"0","summary":"经过数年不佳表现后，2025年生物科技股的趋势可能开始好转，但仍需谨慎挑选一些最具创新力的公司进行投资。“专利悬崖今年开始显现，但将在2025和2026年加剧，”他说。“总之，2025年下半年可能将Insmed转型为一家拥有多种商业化产品并在两个大型适应症中启动关键研究的公司。”摩根士丹利预计，2025年底Rocket的RP-A501基因疗法在二期试验中将取得关键数据，为其股价带来催化剂。","market":"us","thumbnail":"https://community-static.tradeup.com/news/2b99d2790d61544d0e8cfc36cd09b3ab","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/2b99d2790d61544d0e8cfc36cd09b3ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"估值洼地之下，2025年这些生物科技股股价有望突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","RCKT","JNJ","LEGN","RHHBY","ABBV","JAZZ","XBI","BIIB"],"gpt_icon":1},{"id":"2495568504","title":"罗氏(RHHBY.US)CEO回应增长问题：公司没有裁员计划 业务很健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2495568504","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495568504?lang=zh_cn&edition=fundamental","pubTime":"2024-12-30 10:22","pubTimestamp":1735525366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士制药公司罗氏首席执行官Thomas Schinecker表示，公司没有裁员计划，其业务也很健康。据了解，目前罗氏的股价已远远低于2022年4月的峰值，在其治疗癌症等疾病的药物开发最近遭遇挫折的背景下，该公司首席执行官被问及该公司的人员配置计划。当被问及该公司是否计划裁员时，Schinecker在上周日接受采访时表示：“员工数量保持不变，甚至略有增加。”当被问及罗氏计划中的减肥药物何时上市时，Schinecker表示可能在2029年左右或更早。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1230641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2493787064","title":"罗氏(RHHBY)莫妥珠单抗注射液在华批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2493787064","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493787064?lang=zh_cn&edition=fundamental","pubTime":"2024-12-23 15:36","pubTimestamp":1734939418,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据中国国家药监局(NMPA)官网最新公示，罗氏(RHHBY)申报的莫妥珠单抗注射液(mosunetuzumab)上市申请已获得批准。根据中国国家药监局药品审评中心(CDE)优先审评公示，该药本次用于治疗既往接受过至少两种系统性治疗的复发或难治性滤泡性淋巴瘤(FL)成人患者。公开资料显示，莫妥珠单抗是一款靶向B细胞表面的CD20抗原和T细胞表面的CD3受体的T细胞衔接双特异性抗体。该药代表着一种无化疗、现货型新免疫治疗选择，并且可以在门诊输液治疗。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"283581","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2493789682","title":"罗氏(RHHBY.US)双抗癌症疗法“莫妥珠单抗”在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2493789682","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493789682?lang=zh_cn&edition=fundamental","pubTime":"2024-12-23 14:49","pubTimestamp":1734936591,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月23日，中国国家药监局官网最新公示，罗氏申报的莫妥珠单抗注射液上市申请已获得批准。公开资料显示，莫妥珠单抗是一款靶向B细胞表面的CD20抗原和T细胞表面的CD3受体的T细胞衔接双特异性抗体。该药此前曾获FDA授予突破性疗法认定和孤儿药资格。2022年6月，莫妥珠单抗在欧盟获批，用于治疗复发/难治性滤泡性淋巴瘤成人患者，他们已经接受过至少两种前期系统治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"罗氏(RHHBY.US)双抗癌症疗法“莫妥珠单抗”在中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2488522130","title":"罗氏(RHHBY.US)达成近9亿美元合作 开发自身免疫性疾病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2488522130","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488522130?lang=zh_cn&edition=fundamental","pubTime":"2024-12-04 15:26","pubTimestamp":1733297164,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，COUR Pharmaceuticals宣布与罗氏旗下基因泰克达成战略合作与许可协议，双方将共同开发和商业化COUR的专有免疫耐受纳米颗粒疗法，用于治疗自身免疫性疾病。根据协议条款，COUR将获得4000万美元的预付款和近期里程碑付款，此外，还可获得超过9亿美元的开发、商业化和销售里程碑款项。根据合作协议，COUR负责完成前期临床开发和生产技术转移，而基因泰克将承担临床开发、监管申报及商业化的相关工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)达成近9亿美元合作 开发自身免疫性疾病疗法","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","RHHBY","03165"],"gpt_icon":0},{"id":"2486025970","title":"罗氏(RHHBY)拟收购生物制药企业Poseida Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2486025970","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486025970?lang=zh_cn&edition=fundamental","pubTime":"2024-11-26 16:57","pubTimestamp":1732611428,"startTime":"0","endTime":"0","summary":"金吾财讯 | 瑞士罗氏公司于本周二宣布，计划以每股9美元的价格收购位于加州的生物制药企业Poseida Therapeutics，收购完成后，该公司的总股本价值将达到10亿美元。此外，罗氏还提出，Poseida的股东将额外获得每股4美元的不可交易的或有价值权（CVR），使得此次交易的总价值最高可达约15亿美元。预计该交易将在2025年的第一季度内完成。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"282405","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTX","BK4007","BK4139","RHHBY","LENZ","03165"],"gpt_icon":0},{"id":"1129074050","title":"罗氏将以15亿美元的价格收购美国生物制药公司Poseida","url":"https://stock-news.laohu8.com/highlight/detail?id=1129074050","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129074050?lang=zh_cn&edition=fundamental","pubTime":"2024-11-26 16:08","pubTimestamp":1732608480,"startTime":"0","endTime":"0","summary":"交易预计将于2025年第一季度完成。","market":"us","thumbnail":"https://static.tigerbbs.com/2259104638112bdad171cd2b1be81aac","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2259104638112bdad171cd2b1be81aac"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"罗氏将以15亿美元的价格收购Poseida","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","PSTX"],"gpt_icon":0},{"id":"2483047599","title":"罗氏(RHHBY.US)达成抗癌小分子研发合作 或投资超18亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483047599","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483047599?lang=zh_cn&edition=fundamental","pubTime":"2024-11-13 14:39","pubTimestamp":1731479960,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，Flare Therapeutics宣布已与罗氏达成战略发现合作。作为合作的一部分，Flare Therapeutics将获得7000万美元的预付款，并有资格获得可能超过18亿美元的发现、开发和商业化里程碑等款项。自成立以来，Flare Therapeutics迅速建立其新兴项目管线，包含其主打项目FX-909，这是一种靶向PPARG、潜在\"first-in-class\"的口服小分子抑制剂。PPARG是晚期尿路上皮癌管腔谱系细胞的主要调节因子，FX-909目前正处于1期研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"盘前","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1746072000000}}}